American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: Status report 2002

Journal of Clinical Oncology

Volumn 20, Issue 15, 2002, Pages 3317-3327

  Winer, Eric P ^a   Hudis, Clifford ^a   Burstein, Harold J ^a   Chlebowski, Rowan T ^a   Ingle, James N ^a   Edge, Stephen B ^a   Mamounas, Eleftherios P ^a   Gralow, Julie ^a   Goldstein, Lori J ^a   Pritchard, Kathleen I ^a   Braun, Susan ^a   Cobleigh, Melody A ^a   Langer, Amy S ^a   Perotti, Judy ^a   Powles, Trevor J ^a   Whelan, Timothy J ^a   Browman, George P ^a  

^a AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN; TRIAZOLE DERIVATIVE;

ALGORITHM; ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL PRACTICE; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; FATIGUE; HOT FLUSH; HUMAN; MEDICAL SOCIETY; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; ENZYME INHIBITORS; EVIDENCE-BASED MEDICINE; EXPERT TESTIMONY; FEMALE; HUMANS; NITRILES; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TAMOXIFEN; TRIAZOLES;

EID: 0036682039     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.06.020     Document Type: Article

References (53)

1. Tamoxifen for early breast cancer: An overview of the randomised trials
2. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
3. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer: Scottish Cancer Trials Breast Group
4. Results of two or five years-of adjuvant tamoxifen correlated to steroid receptor and S-phase levels: South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group
5. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial
6. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
7. A meta-analysis of vascular and neoplastic events associated with tamoxifen
8. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
9. National Institutes of Health Consensus Development Conference statement: Adjuvant therapy for breast cancer. November 1-3, 2000
10. Ovarian ablation in early breast cancer: Overview of the randomised trials
11. Ovarian ablation as adjuvant therapy for breast cancer
12. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: The Scottish trial
13. Comparable effect of ovarian ablation and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients
14. Zoladex vs CMF as adjuvant therapy in pre-/perimenopausal early (node positive) breast cancer: Preliminary efficacy - QOL and BMD results from the ZEBRA study
15. Comparison of adjuvant therapy with tamoxifen and goserelin vs CMF in premenopausal stage I and II hormone-responsive breast cancer patients: Four-year results of Austrian Breast Cancer Study Group Trial 5
16. Complete hormonal blockage versus chemotherapy in premenopausal early-stage breast cancer patients with positive hormone-receptor and 1-3 node-positive tumor, results of the FASG 06 trial
17. Aromatase inhibitors in the treatment and prevention of breast cancer
18. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients
19. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials - Arimidex Study Group
20. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma: Arimidex Study Group
21. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer
22. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
23. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate
24. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial: The Exemestane Study Group
25. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study
26. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial-Arimidex Study Group
27. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group
28. Efficacy of and tolerance to exemestane versus tamoxifen in 1st line hormone therapy of postmenopausal metastatic breast cancer patients: A European Organization for the Research and Treatment of Cancer (EORTC Breast Group) phase II trial with Pharmacia and Upjohn
29. A double blind randomised clinical trial of adjuvant aminoglutethimide versus placebo given to post menopausal patients with histologically confirmed stage II breast cancer
30. Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: Analysis at 8 years
31. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: Results of an Italian cooperative study
32. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in post-menopausal women
33. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines
34. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer
35. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study
36. Letrozole (Femara) vs anastrozole (Arimidex): Second-line treatment in postmenopausal women with advanced breast cancer
37. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma
38. Tamoxifen-induced hot flashes
39. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: A comparative endocrine study
40. Combined use of goserelin and anastrozole in premenopausal women with metastatic breast cancer
41. Primary care for survivors of breast cancer
42. Reproductive issues
43. Risk of menopause during the first year after breast cancer diagnosis
44. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: Tamoxifen and raloxifene
45. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition
46. Results of prolonged adjuvant tamoxifen therapy of breast cancer correlated to steroid receptor, S-phase and ERBB2 levels
47. HER2 overexpression predicts adjuvant tamoxifen (TAM) failure for early breast cancer (EBC): Complete data at 20 yr of the Naples GUN randomized trial
48. C-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
49. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group study
50. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer
51. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial
52. Serum estradiol level and risk of breast cancer during treatment with raloxifene
53. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease